Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Evid Based Complement Alternat Med. 2012;2012:732195. doi: 10.1155/2012/732195. Epub 2012 Feb 16.
Objective. The aim of this study is to measure the reliability and external validity of AMSTAR by applying it to a sample of TCM systematic reviews. Study Design and Methods. We tested the agreement, reliability, construct validity, and feasibility of AMSTAR through comparisons with OQAQ. Statistical analyses were performed by using SPSS 13.0. Results. A random of sample with 41 TCM systematic reviews was selected from a database. The interrater agreement of the individual items of AMSTAR was moderate with a mean kappa of 0.50 (95% CI: 0.26, 0.73). The ICC for AMSTAR against OQAQ (total score of 9 items, excluding item 10) was 0.87 (95% CI: 0.76, 0.93). Conclusions. Although there is room for improvement on few items, the new tool is reliable, valid, and easy to use for methodological quality assessment of systematic reviews on TCM.
目的。本研究旨在通过将 AMSTAR 应用于中医系统评价样本,来衡量其可靠性和外部有效性。
研究设计和方法。我们通过与 OQAQ 的比较来测试 AMSTAR 的一致性、可靠性、结构有效性和可行性。使用 SPSS 13.0 进行统计分析。
结果。从数据库中随机抽取 41 篇中医系统评价进行样本分析。AMSTAR 各项目的组内一致性中等,平均kappa 值为 0.50(95%置信区间:0.26,0.73)。AMSTAR 与 OQAQ(9 项总分,不包括第 10 项)的 ICC 为 0.87(95%置信区间:0.76,0.93)。
结论。尽管在少数项目上还有改进的空间,但新工具对于中医系统评价的方法学质量评估是可靠、有效且易于使用的。